{"id":"sg301","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SG301 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"SG301 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:10.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06144710","phase":"PHASE1","title":"SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2023-11-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":48},{"nctId":"NCT07447986","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2026-03-15","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":120},{"nctId":"NCT07087314","phase":"PHASE2","title":"A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence","status":"RECRUITING","sponsor":"Mao Jianhua","startDate":"2025-08-25","conditions":"Nephrotic Syndrome in Children","enrollment":30},{"nctId":"NCT06508983","phase":"PHASE3","title":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2024-06-14","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":360},{"nctId":"NCT04684108","phase":"PHASE1","title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2021-11-04","conditions":"Relapsed or Refractory Multiple Myeloma, Hematological Malignancy","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SG301","genericName":"SG301","companyName":"Hangzhou Sumgen Biotech Co., Ltd.","companyId":"hangzhou-sumgen-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SG301 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}